Elucidating the role of clofazimine for the treatment of tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 12, 2016, Pages S52-S57

  O'Donnell, M R ^a,b,c   Padayatchi, N ^c   Metcalfe, J Z ^d  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CFZ; TB; Treatment

Indexed keywords

AMIKACIN; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; DISEASE MODEL; DRUG EFFICACY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISCOLORATION; TRANSLATIONAL RESEARCH; TREATMENT DURATION; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; OBSERVATIONAL STUDY;

ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85014588335     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0073     Document Type: Article

References (46)

1. Barry V C, Belton J G, Conalty M L, et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 1957; 179: 1013-1015.
2. Barry V C, Buggle K, Byrne J, Conalty M L, Winder F. Absorption, distribution and retention of the riminocompounds in the experimental animal. Ir J Med Sci 1960; 416: 345-352.
3. Barry V C, Conalty M L. Antituberculosis activity in the phenazine series. II. N3-substituted anilinoaposafranines (rimino-compounds) and some derivatives. Am Rev Tuberc 1958; 78: 62-73.
4. Chang Y T. Chemotherapy of murine leprosy. IV. The effects of amithiozone (TB1/698), p-aminosalicylic acid (PAS), B 283 (a phenazine pigment), five antibiotics and three diphenylthiourea compounds on mouse leprosy. Int J Lepr 1955; 23: 167-180.
5. Degang Y, Akama T, Hara T, et al. Clofazimine modulates the expression of lipid metabolism proteins in Mycobacterium leprae-infected macrophages. PLOS Negl Trop Dis 2012; 6: e1936.
6. Yano T, Kassovska-Bratinova S, Teh J S, et al. Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011; 286: 10276-10287.
7. Hartkoorn R C, Uplekar S, Cole S T. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-2981.
8. Koul A, Vranckx L, Dhar N, et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun 2014; 5: 3369.
9. Fukutomi Y, Maeda Y, Makino M. Apoptosis-inducing activity of clofazimine in macrophages. Antimicrob Agents Chemother 2011; 55: 4000-4005.
10. Swanson R V, Adamson J, Moodley C, et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother 2015; 59: 3042-3051.
11. Nix D E, Adam R D, Auclair B, Krueger T S, Godo P G, Peloquin C A. Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) 2004; 84: 365-373.
12. Schaad-Lanyi Z, Dieterle W, Dubois J P, Theobald W, Vischer W. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobact Dis 1987; 55: 9-15.
13. Grant S S, Kaufmann B B, Chand N S, Haseley N, Hung D T. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci USA 2012; 109: 12147-12152.
14. Zhang D, Liu Y, Zhang C, et al. Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents. Molecules 2014; 19: 4380-4394.
15. Aung K J, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
16. Van Deun A, Maug A K, Salim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
17. Tyagi S, Ammerman N C, Li S Y, et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci USA 2015; 112: 869-874.
18. Grosset J H, Tyagi S, Almeida D V, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013; 188: 608-612.
19. Irwin S M, Gruppo V, Brooks E, et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 2014; 58: 4026-4034.
20. Prideaux B, Via L E, Zimmerman M D, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 2015; 21: 1223-1227.
21. Lanoix J P, Ioerger T, Ormond A, et al. Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum. Antimicrob Agents Chemother 2015; 60: 735-743.
22. Mitchison D A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147: 1062-1063.
23. Diacon A H, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015; 191: 943-953.
24. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015; 45: 161-170.
25. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
26. Geerligs WA, Van Altena R, De Lange W C M, Van Soolingen D, Van Der Werf T S. Multidrug-resistant tuberculosis: longterm treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-764.
27. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
28. Senaratne W V. Outcome of treatment of multidrug resistant tuberculosis. Ceylon Med J 2004; 49: 86-87.
29. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-185.
30. Xu H B, Jiang R H, Xiao H P. Clofazimine in the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect 2012; 18: 1104-1110.
31. Piubello A, Harouna S H, Souleymane M B, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-1194.
32. Kuaban C, Noeske J, Rieder H L, Äit-Khaled N, Abena Foe J L, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517-524.
33. Heysell S K, Ahmed S, Ferdous S S, et al. Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice. PLOS ONE 2015; 10: e0116795.
34. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom W N. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008; 134: 187-192.
35. Mitnick C D, Shin S S, Seung K J, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
36. Padayatchi N, Gopal M, Naidoo R, et al. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. J Antimicrob Chemother 2014; 69: 3103-3107.
37. Yoo J W, Lyu J, Lee S D, Kim W S, Kim D S, Shim T S. Clinical experience of using clofazimine to treat multidrug-resistant tuberculosis [Correspondence]. Int J Tuberc Lung Dis 2013; 17: 1243-1244.
38. Gopal M, Padayatchi N, Metcalfe J Z, O'Donnell M R. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17: 1001-1007.
39. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68: 284-293.
40. Hwang T J, Dotsenko S, Jafarov A, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 2014; 4: e004143.
41. Chang K C, Yew W W, Tam C M, Leung C C. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57: 4097-4104.
42. Xu H B, Jiang R H, Li L, Xiao H P. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis 2012; 16: 358-363.
43. Nunn A J, Rusen I D, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014; 15: 353.
44. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.
45. Moore V J. A review of side-effects experienced by patients taking clofazimine. Lepr Rev 1983; 54: 327-335.
46. Harausz E, Cox H, Rich M, Mitnick C D, Zimetbaum P, Furin J. QTc prolongation and treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2015; 19: 385-391.